Literature DB >> 11564827

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

H R Salih1, H M Schmetzer, C Burke, G C Starling, R Dunn, R Pelka-Fleischer, V Nuessler, P A Kiener.   

Abstract

Expression of CD137 ligand (4-1BBL), a member of the TNF family of proteins, has been reported on several types of APCs, various carcinoma cells, and can be induced on activated T cells. In this study, we report that the soluble ligand was released constitutively at low levels from leukocytes and at higher levels following cellular activation. Release from cells was blocked by addition of a metalloproteinase inhibitor which concomitantly caused the accumulation of 4-1BBL on the cell surface. In addition, we show that a soluble form of 4-1BBL was present at high levels in the sera of some patients with various hematological diseases, but only at low levels in healthy donors. Soluble 4-1BBL was active in that it competed with recombinant 4-1BBL for binding to the 4-1BB receptor and was able to costimulate IL-2 and IFN-gamma release from peripheral T cells. These results indicate that the release of soluble 4-1BBL from the cell surface is mediated by one or more sheddases and likely regulates 4-1BB-4-1BBL interactions between cells in vivo. Cleavage of 4-1BBL to an active soluble form would alter both proximal and distal cellular responses, including cell survival and costimulatory or inflammatory responses, that are mediated through the 4-1BB pathway. This, in turn, would likely alter disease progression or outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564827     DOI: 10.4049/jimmunol.167.7.4059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Levels of 4-1BB transcripts and soluble 4-1BB protein are elevated in the adipose tissue of human obese subjects and are associated with inflammatory and metabolic parameters.

Authors:  T H Tu; C-S Kim; J-H Kang; I S Nam-Goong; C W Nam; E S Kim; Y I Kim; J I Choi; T Kawada; T Goto; T Park; J H Yoon Park; M-S Choi; R Yu
Journal:  Int J Obes (Lond)       Date:  2013-11-27       Impact factor: 5.095

2.  Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum.

Authors:  Guangbo Zhang; Jianquan Hou; Jinfang Shi; Gehua Yu; Binfeng Lu; Xueguang Zhang
Journal:  Immunology       Date:  2008-01-09       Impact factor: 7.397

Review 3.  Integrating costimulatory agonists to optimize immune-based cancer therapies.

Authors:  Angela D Pardee; Amy K Wesa; Walter J Storkus
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

Review 4.  The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis.

Authors:  Ricardo F Antunes; Juan Carlos Kaski; Ingrid E Dumitriu
Journal:  J Biomed Biotechnol       Date:  2011-12-22

5.  Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines.

Authors:  Gregory Lee Szeto; Debra Van Egeren; Hermoon Worku; Armon Sharei; Brian Alejandro; Clara Park; Kirubel Frew; Mavis Brefo; Shirley Mao; Megan Heimann; Robert Langer; Klavs Jensen; Darrell J Irvine
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

6.  CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals.

Authors:  Mayumi Yoshimori; Ken-Ichi Imadome; Honami Komatsu; Ludan Wang; Yasunori Saitoh; Shoji Yamaoka; Tetsuya Fukuda; Morito Kurata; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 7.  SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.

Authors:  Wei-Sheng Tien; Jun-Hong Chen; Kun-Pin Wu
Journal:  BMC Bioinformatics       Date:  2017-03-14       Impact factor: 3.169

8.  Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.

Authors:  S Michael Chin; Christopher R Kimberlin; Zygy Roe-Zurz; Pamela Zhang; Allison Xu; Sindy Liao-Chan; Debasish Sen; Andrew R Nager; Nicole Schirle Oakdale; Colleen Brown; Feng Wang; Yuting Yang; Kevin Lindquist; Yik Andy Yeung; Shahram Salek-Ardakani; Javier Chaparro-Riggers
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

9.  CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages.

Authors:  Pengling Jiang; Wenjuan Gao; Tiansi Ma; Rongrong Wang; Yongjun Piao; Xiaoli Dong; Peng Wang; Xuehui Zhang; Yanhua Liu; Weijun Su; Rong Xiang; Jin Zhang; Na Li
Journal:  Theranostics       Date:  2019-05-09       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.